Cas:33007-09-9 furo[3,2-c]pyridin-4-amine manufacturer & supplier

Chemical Name:furo[3,2-c]pyridin-4-amine

CAS.NO:33007-09-9

Synonyms:Amino-4-furo<3,2-c>pyridin;furo[3,2-c]pyridin-4-ylamine;4-aminofuro[3,2-c]pyridine

Molecular Formula:C₇H₆N₂O

Molecular Weight:134.13500

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:52.05000

Exact Mass:134.04800

LogP:1.99120

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like Amino-4-furo&lt chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-aminofuro[3,2-c]pyridine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Amino-4-furo&lt Use and application,Amino-4-furo&lt technical grade,usp/ep/jp grade.

Related News: Biogen last month revived its plans to seek U.S. approval for its aducanumab treatment after announcing in March that it would terminate two large clinical trials for the drug. But some analysts believed FDA approval is highly unlikely. furo[3,2-c]pyridin-4-amine manufacturer Most foreign drugmakers offered Beijing the lowest prices globally in a recent round of negotiations in order to get some of their new products included in national insurance program, a move that will help them gain access to more patients in less-affluent cities, officials said on Thursday. furo[3,2-c]pyridin-4-amine supplier The cell product candidate is being developed under a collaboration with Memorial Sloan Kettering Cancer Center (MSK) led by Michel Sadelain, MD, PhD. furo[3,2-c]pyridin-4-amine vendor Biogen last month revived its plans to seek U.S. approval for its aducanumab treatment after announcing in March that it would terminate two large clinical trials for the drug. But some analysts believed FDA approval is highly unlikely. furo[3,2-c]pyridin-4-amine factory Biogen last month revived its plans to seek U.S. approval for its aducanumab treatment after announcing in March that it would terminate two large clinical trials for the drug. But some analysts believed FDA approval is highly unlikely.